Cambium Bio has raised just over A$1 million through a strategic placement at a 17% premium, boosting a key shareholder’s stake as it advances its pivotal Phase 3 trial for dry eye disease.
- A$1.008 million raised via placement at A$0.48 per share
- Placement price 17.1% above prior closing share price
- Strategic shareholder increases stake from 12.25% to 18.5%
- Funds earmarked for pivotal Phase 3 trial of Elate Ocular®
- Shares issued under existing 10% placement capacity without approval
Strategic Shareholder Boosts Stake with Premium Placement
Cambium Bio Limited (ASX:CMB) has successfully raised A$1.008 million through a placement of 2.1 million new shares priced at A$0.48 each, representing a notable 17.1% premium to the previous closing price of A$0.41. The placement was subscribed entirely by existing strategic shareholder Mr Chun Yi Wu, also known as Brandon Wu, who is active in the regenerative medicine sector. This transaction increases his relevant interest in Cambium Bio from approximately 12.25% to 18.5%, signaling strong insider confidence ahead of the company’s critical clinical milestones.
Capital Raise Supports Pivotal Phase 3 Dry Eye Trial
The proceeds from this placement will directly fund Cambium Bio’s pivotal Phase 3 trial of Elate Ocular®, its lead biologic candidate targeting moderate to severe dry eye disease. The Phase 3 program, designed as a single 475-patient trial, has received FDA confirmation that it will be sufficient to underpin a Biologics License Application submission. This streamlined approach aims to reduce development complexity and accelerate potential regulatory approval.
Shares issued under this placement will be allocated through the company’s existing 10% placement capacity under ASX Listing Rule 7.1A, which means no shareholder approval was necessary. Settlement and quotation of the new shares are expected within five business days, maintaining momentum in Cambium Bio’s funding strategy.
CEO Highlights Growing Investor Interest and Strategic Alignment
CEO Karolis Rosickas emphasised the significance of the placement reflecting confidence in Cambium Bio’s value and the promising outlook for Elate Ocular®. He noted the growing interest from strategic partners and investors in addressing the unmet needs of dry eye disease patients, highlighting the demand for novel therapeutics with superior efficacy and safety profiles. The premium pricing of the placement shares underscores this positive sentiment.
While the company continues to advance its clinical pipeline, including its Progenza™ stem cell platform for tissue repair, the immediate focus remains on progressing the Phase 3 trial to pivotal readouts that could significantly impact the company’s commercial trajectory.
Bottom Line?
Cambium Bio’s premium placement to a strategic insider bolsters its war chest for a pivotal clinical milestone, setting the stage for upcoming trial progress and regulatory engagement.
Questions in the middle?
- How will the increased stake of Mr Wu influence Cambium Bio’s strategic direction and future capital raises?
- What are the detailed timelines and milestones for the Phase 3 Elate Ocular® trial beyond patient enrolment?
- Could further premium placements or partnerships emerge as the Phase 3 program advances?